Susquehanna International Group
OTLK icon

Susquehanna International Group’s Outlook Therapeutics OTLK Stock Holding History

Susquehanna International Group’s Portfolio OTLK Stock Details OTLK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-367,800
Closed -$581K – 13856
2025
Q4 		$581K Buy
+367,800
New +$588K ﹤0.01% 8442
2025
Q1 		– Sell
-21,200
Closed -$40.1K – 13196
2024
Q4 		$40.1K Sell
21,200
-21,000
-50% -$86.4K ﹤0.01% 11762
2024
Q3 		$225K Buy
42,200
+29,100
+222% +$213K ﹤0.01% 10220
2024
Q2 		$96.7K Buy
+13,100
New +$105K ﹤0.01% 11050

Other funds holding OTLK

AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
GWM
Gilpin Wealth Management Denver, Colorado $145M AUM
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Commonwealth Equity Services
Commonwealth Equity Services Waltham, Massachusetts $79.5B AUM 27.1% 1-Year Est. Return
WAM
Warberg Asset Management Winnetka, Illinois $600M AUM 23.37% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
NMC
Nine Masts Capital Central, Hong Kong $693M AUM 31.93% 1-Year Est. Return
CCM
Connective Capital Management Palo Alto, California $121M AUM 39.82% 1-Year Est. Return

Susquehanna International Group's OTLK Position: Q1 2026 in Review

Susquehanna International Group reduced its Outlook Therapeutics (OTLK) stake by 22% in Q1 2026, selling an estimated $16.4K and leaving 134,084 shares worth $27.6K. The position accounts for ﹤0.01% of the portfolio, ranked #12790.

Susquehanna International Group first reported a position in OTLK in Q1 2018 and has held it in 19 quarters since. The position peaked at $373K in Q1 2021. 54 funds tracked by Wall St. Rank hold OTLK as of Q1 2026.

  • Susquehanna International Group held 134,084 shares of Outlook Therapeutics worth $27.6K as of Q1 2026.
  • Susquehanna International Group sold 37,938 Outlook Therapeutics shares in Q1 2026, an estimated $16.4K.
  • Outlook Therapeutics made up ﹤0.01% of Susquehanna International Group's portfolio in Q1 2026, its #12790 holding.
  • Susquehanna International Group first reported a position in Outlook Therapeutics in Q1 2018 and has held it in 19 quarters since.
  • Susquehanna International Group's Outlook Therapeutics position peaked at $373K in Q1 2021.
  • 54 funds tracked by Wall St. Rank held Outlook Therapeutics as of Q1 2026.

Based on Susquehanna International Group's 13F filing for Q1 2026, filed 15 May 2026.